Allergy Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The Allergy Diagnostics Market size is estimated at USD 5.70 billion in 2024, and is expected to reach USD 9.80 billion by 2029, growing at a CAGR of 11.20% during the forecast period (2024-2029).

Key Highlights

• The pandemic significantly impacted the growth of the allergic diagnostics market since several clinics that perform allergy diagnostic tests had to shut down temporarily due to the lockdown restrictions. For instance, according to an article published by the Clinical and Translational Allergy in January 2022, the pandemic had an impact on medical professionals who treated allergic patients in terms of diagnostic, management, and treatment techniques, including allergen immunotherapy (AIT) for food, insect venom, and respiratory allergies. Moreover, most allergy/immunology care was delayed or postponed or handled through virtual care.
• For patients with asthma of a certain severity, there was a limited provision for face-to-face visits under critical conditions. Such factors have impacted the market growth during the pandemic. However, as the pandemic restrictions are eased, the studied market is expected to witness significant growth in the coming years due to the increase in allergy cases and rapid technological advancements in allergy diagnostics.
• Certain factors that are propelling the market growth are increasing incidences of allergic diseases and environmental pollution. The rising incidences of allergic diseases such as hives, atopic dermatitis, allergic conjunctivitis, and various food allergies are expected to increase market growth. For instance, as per the January 2023 update by CDC, nearly 1 in 3 United States adults and more than 1 in 4 United States children reported having a seasonal allergy, eczema, or food allergy in 2021, according to new data from CDC’s National Center for Health Statistics. Almost 6% of US adults and children had a food allergy, with Black, non-Hispanic adults and children one of the most likely to report this type of allergy. Also, approximately 25.7% of adults had a seasonal allergy, 7.3% had eczema, and 6.2% had a food allergy. Thus, a high prevalence of allergy cases is likely to increase the demand for allergy diagnostics, thereby boosting market growth.
• Furthermore, the increasing focus of the companies on research and development activities to develop novel diagnostic products, tests, or kits to cater to high unmet medical needs is highly impacting the market’s growth. For instance, in May 2022, Amulet, a manufacturer of the smallest, fastest, and sleekest molecular detection technology, launched Allergy Amulet, a consumer brand with a signature wearable that alerts people to allergens in their food, and Amulet Scientific, a commercial brand that equips industry with a detection platform for identifying a range of molecular targets, including food toxins and environmental contaminants.
• Similarly, in October 2022, Scottish tech startup LiberEat secured USD 0.26 million (GBP 209 thousand) in grant funding from Innovate UK to accelerate the development of the Aberdeen-based firm’s allergen platform and further advance its machine learning capabilities.
• Thus, owing to the increase in the prevalence of allergy cases and the rise in investment as well as product launches for allergy detection, the studied market is expected to witness significant growth over the forecast period. However, the lack of awareness about allergic diseases and the affordability of allergy diagnostics are likely to impede the market growth over the forecast period.

Allergy Skin Test Market Trends

Inhaled Allergens Segment Expects to Register a High CAGR in the Allergy Diagnostics Market Over the Forecast Period

• Inhaled allergies are the most common type of allergy. They can be triggered by several airborne pollutants, both indoors and outdoors. Seasonal inhalant allergies, often known as hay fever, are particularly prevalent. Common outdoor allergens include pollen, mold spores, fungi, dust, and other irritants, while indoor allergens encompass animal dander, dust mites, fragrances, and more.
• The inhaled allergens segment is anticipated to experience substantial growth in the allergy diagnostics market over the forecast period. This surge is attributed to factors such as increasing environmental pollution, a rise in respiratory allergies and asthma cases globally, and the heightened demand for allergy testing. For example, according to 2022 statistics from the National Health Service, approximately 1.17 million people in England were diagnosed with chronic obstructive pulmonary disorder (COPD) in 2020-2021, accounting for 1.9% of the total population.
• Additionally, the Occupational Lung Disease statistics in Great Britain for 2021 recorded an estimated 17,000 new cases of breathing and lung problems each year, many of which were either caused or exacerbated by workplace conditions. These alarming rates of respiratory issues are projected to drive the demand for allergy diagnostic devices during the forecast period.
• Moreover, due to rapid urbanization, industrialization, and resulting lifestyle changes, many countries have experienced a sharp increase in air pollutants, leading to a rise in allergies like asthma and allergic rhinitis. For example, according to the World Air Quality Report by IQAir in March 2022, India ranked as the fifth most polluted country among 117 countries, regions, and territories worldwide. The annual average PM2.5 levels reached 58.1 micrograms per cubic meter (µg/m3) in India in 2021. Consequently, with the escalation of airborne allergens, the necessity for early diagnosis and treatment is expected to grow, thus fueling the demand for diagnostic tests and systems that identify the pollutants causing allergies, ultimately boosting market growth.
• Additionally, the presence of key market players and their strategic initiatives is projected to reinforce the demand for allergy diagnostic devices. For instance, in June 2022, Oncologica launched Allergyfocus, a new antibody allergy test that swiftly and accurately detects 99% of common global allergies. This test provides a comprehensive, personalized antibody profile of a patient’s allergy triggers for precise diagnosis.
• Therefore, owing to the rise in respiratory diseases and the strategic efforts of major industry players, this segment is expected to witness significant growth throughout the forecast period.

North America is Anticipated to Hold a Significant Market Share Over the Forecast Period

• North America is poised to experience substantial market growth in the field of allergy diagnostics. This growth can be attributed to various factors, including the rising incidence and prevalence of allergic diseases and related conditions, environmental pollution, increased healthcare spending, and heightened company activities.
• For instance, according to the December 2022 update from the CDC, in 2021, 4.6% of adults had been diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, or chronic bronchitis, with 781,000 emergency department visits primarily due to COPD.
• The surge in COPD cases directly correlates with an increased demand for allergy diagnostic devices, thereby stimulating market growth. Additionally, the region's escalating company activities and the surge in product approvals are projected to further fuel market expansion during the forecast period.
• For example, in August 2022, the FDA approved Thermo Fisher’s ImmunoCAP Specific IgE (sIgE) Allergen Components for wheat and sesame allergies for in vitro diagnostic use, aiding healthcare providers in identifying these allergies in at-risk patients. Similarly, the FDA's approval of the ImmunoCAP Specific IgE alpha-Gal Allergen Component test in September 2021 assists in diagnosing sensitization to the alpha-Gal carbohydrate found in mammalian (red) meat, assessing the risk of anaphylactic reactions.
• Moreover, the September 2022 collaboration between RxCap, Inc. and ZEPHYRx LLC to integrate their respective remote monitoring platforms enables the monitoring of lung function in patients with serious pulmonary conditions by RxCap's enterprise customers, such as providers and payers.
• Therefore, the confluence of factors, including the rise in allergy-causing diseases and strategic initiatives by key industry players, is expected to propel significant market growth in the North American region throughout the forecast period.

Allergy Skin Test Industry Overview

The allergy diagnostics market is moderately fragmented and consists of several market players. The key market players are involved in various strategic activities such as partnerships, product launches, and agreements, which are further expected to bolster the market growth. The presence of major market players, such as BioMerieux SA, Thermo Fischer Scientific Inc, Omega Diagnostics, Siemens Healthineers AG, and Danaher Corporation, intensifies the market competition.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.